Showing results (61-70 of 86) with videos related to
Sort By:
Pageof 9
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 20, 2025
Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myelomaCiara L Freeman, Julieta Abraham-Miranda, Meghan Menges, et al.Transplantation and Cellular Therapy|December 20, 2023
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T TherapyOthman S Akhtar, Karnav Modi, Jongphil Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T ConsortiumDoris K Hansen, Surbhi Sidana, Lauren C Peres, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Adriana Zingone, Maciej Kmieciak, et al.Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.Clinical Lymphoma, Myeloma & Leukemia|August 21, 2018
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell LymphomaVictor Yazbeck, Danielle Shafer, Edward B Perkins, et al.American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.Blood|December 9, 2024
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomesCiara L Freeman, Jerald Noble, Meghan Menges, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.Pageof 9